Supplementary Table 1.
Risk of bias assessment table
| Burnett-Bowie 2009 | Risk Of Bias | Author Judgement |
|---|---|---|
| Random Sequence Generation (Selection Bias) | Low Risk | Randomised, double-blind, placebo controlled study |
| Allocation Concealment (Selection Bias) | Low Risk | Subjects were randomized by computer-generated assignment in a blinded 1 : 1 ratio |
| Blinding Of Participants & Personal (Performance Bias) | Low Risk | Yes, double blinded RCT |
| Blinding Of Outcome Assessment (Detection Bias) | Low Risk | Yes, double blinded RCT |
| Incomplete Outcome Data (Attrition Bias) | High Risk | 69 out of 88 patients completed the study (78.4%) Hence attrition rate was high (>20%) |
| Selective Reporting (Reporting Bias) | Low Risk | All pre-specified outcomes were reported |
| Other Biases | Low Risk | This work was supported by National Institute of Health grants K23-RR-161310 (to BZL), R01-AG-025099-03 (to BZL), M01-RR-01066 (to the Mallinckrodt GCRC) and AstraZeneca Pharmaceuticals. |
|
| ||
| Colleluori 2020 | Risk Of Bias | Author Judgement |
|
| ||
| Random Sequence Generation (Selection Bias) | Low Risk | Randomised, double-blind, placebo controlled study |
| Allocation Concealment (Selection Bias) | Low Risk | Participants were randomized by the MEDVAMC pharmacy from a list generated by a research biostatistician to one of two treatment groups |
| Blinding Of Participants & Personel (Performance Bias) | Low Risk | Yes, double blinded RCT |
| Blinding Of Outcome Assessment (Detection Bias) | Low Risk | Yes, double blinded RCT |
| Incomplete Outcome Data (Attrition Bias) | High Risk | 17 out of 23 patients completed the study (73.91%). Hence attrition rate was high (>20%) |
| Selective Reporting (Reporting Bias) | Low Risk | All Pre-Specified Outcomes Were Reported |
| Other Biases | Low Risk | This research did not receive any specific grant from any funding agency in the public, commercial, or not-for profit sector. |
|
| ||
| Leder 2004 | Risk Of Bias | Author Judgement |
|
| ||
| Random Sequence Generation (Selection Bias) | Low Risk | Randomised, double-blind, placebo controlled study |
| Allocation Concealment (Selection Bias) | Low Risk | Subjects were randomized by computer-generated assignment |
| Blinding Of Participants & Personal (Performance Bias) | Low Risk | Yes, double blinded RCT |
| Blinding Of Outcome Assessment (Detection Bias) | Low Risk | Yes, double blinded RCT |
| Incomplete Outcome Data (Attrition Bias) | Low Risk | All patient outcomes reported. NO drop-outs |
| Selective Reporting (Reporting Bias) | Low Risk | All Pre-Specified Outcomes Were Reported |
| Other Biases | Low Risk | This work was supported by National Institutes of Health Grant K23-RR16310 (to B.Z.L.), the Massachusetts General Hospital Clinical Research Center grant (RR-1066), and AstraZeneca Pharmaceuticals. |
|
| ||
| Leder 2005 | Risk Of Bias | Author Judgement |
|
| ||
| Random Sequence Generation (Selection Bias) | Low Risk | Randomised, double-blind, placebo controlled study |
| Allocation Concealment (Selection Bias) | Low Risk | Subjects were randomized by computer-generated assignment |
| Blinding Of Participants & Personal (Performance Bias) | Low Risk | Yes, double blinded RCT |
| Blinding Of Outcome Assessment (Detection Bias) | Low Risk | Yes, double blinded RCT |
| Incomplete Outcome Data (Attrition Bias) | Low Risk | All patient outcomes reported. NO drop-outs |
| Selective Reporting (Reporting Bias) | Low Risk | All Pre-Specified Outcomes Were Reported |
| Other Biases | Low Risk | This work was supported by National Institutes of Health Grant K23-RR16310 (to B.Z.L.), the Massachusetts General Hospital Clinical Research Center grant (RR-1066), and AstraZeneca Pharmaceuticals. |